<!DOCTYPE html>
<html lang="en-us">
<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="theme" content="hugo-academic">
  <meta name="generator" content="Hugo 0.50" />
  <meta name="author" content="Lena Smith">

  
  
  
  
    
      
    
  
  <meta name="description" content="Background/Objectives: Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and infant hospitalization in the US. RSV prevention evolved in 2023 as nirsevimab and maternal RSV pre-fusion vaccine became available for healthy newborns and infants. This study investigates sociodemographic characteristics associated with RSV immunoprophylaxis. Methods: A cross-sectional survey was conducted from November 2023 through March 2024 among a convenience sample of parents of infants aged &lt;8 months who received newborn care or pediatric ambulatory care at a single academic institution in Central Pennsylvania, USA. Logistic regression examined sociodemographic factors associated with RSV immunoprophylaxis uptake. Given the nirsevimab shortage during the 2023–2024 RSV season, a sensitivity analysis was completed for intended immunoprophylaxis. Results: Among 118 participants, 66.9% received RSV immunoprophylaxis while 74.5% intended to receive nirsevimab. Higher income, private insurance, out-of-home childcare, and an adult/partner working in healthcare were associated with intended nirsevimab receipt. Participation in the Women, Infants and Children program was associated with lower rates of intended nirsevimab receipt. Out-of-home childcare was associated with both RSV immunoprophylaxis uptake and intended nirsevimab receipt. Conclusions: Sociodemographic factors significantly influence the intent to receive nirsevimab and RSV immunoprophylaxis uptake. Having an adult/partner in healthcare was the most significant predictor for intent, suggesting that greater health literacy drives immunization intention. Enrollment in out-of-home childcare was the sole predictor of RSV immunoprophylaxis uptake. These findings highlight the importance of policy initiatives that promote equitable access to RSV immunoprophylaxis, including strategies to address socioeconomic barriers, improve health literacy, and ensure consistent availability of preventive agents for all infants.">

  
  <link rel="alternate" hreflang="en-us" href="/publication/2025-10-pediatr_rep/">

  


  

  
  
  <meta name="theme-color" content="#0095eb">
  
  
  
  
    
  
  
    
    
      
        <link rel="stylesheet" href="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/styles/github.min.css">
      
    
  
  
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.3.7/css/bootstrap.min.css" integrity="sha512-6MXa8B6uaO18Hid6blRMetEIoPqHf7Ux1tnyIQdpt9qI5OACx7C+O3IVTr98vwGnlcg0LOLa02i9Y1HpVhlfiw==" crossorigin="anonymous">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/4.7.0/css/font-awesome.min.css" integrity="sha512-SfTiTlX6kk+qitfevl/7LibUOeJWlt9rbyDn92a1DqWOw9vWG2MFoays0sgObmWazO5BQPiFucnnEAjpAB+/Sw==" crossorigin="anonymous">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.2.5/jquery.fancybox.min.css" integrity="sha256-ygkqlh3CYSUri3LhQxzdcm0n1EQvH2Y+U5S2idbLtxs=" crossorigin="anonymous">
  
  
  
  
  <link rel="stylesheet" href="//fonts.googleapis.com/css?family=Montserrat:400,700%7cRoboto:400,400italic,700%7cRoboto&#43;Mono">
  
  <link rel="stylesheet" href="/styles.css">
  

  
  
  

  
  <link rel="alternate" href="/index.xml" type="application/rss+xml" title="Center for Medical Genomics">
  <link rel="feed" href="/index.xml" type="application/rss+xml" title="Center for Medical Genomics">
  

  <link rel="manifest" href="/site.webmanifest">
  <link rel="icon" type="image/png" href="/img/icon.png">
  <link rel="apple-touch-icon" type="image/png" href="/img/icon-192.png">

  <link rel="canonical" href="/publication/2025-10-pediatr_rep/">

  <meta property="twitter:card" content="summary_large_image">
  
  <meta property="twitter:site" content="@GeorgeCushen">
  <meta property="twitter:creator" content="@GeorgeCushen">
  
  <meta property="og:site_name" content="Center for Medical Genomics">
  <meta property="og:url" content="/publication/2025-10-pediatr_rep/">
  <meta property="og:title" content="Sociodemographic Factors, Intent-Uptake Disparities, and Nirsevimab Availability in Infant RSV Immunoprophylaxis | Center for Medical Genomics">
  <meta property="og:description" content="Background/Objectives: Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and infant hospitalization in the US. RSV prevention evolved in 2023 as nirsevimab and maternal RSV pre-fusion vaccine became available for healthy newborns and infants. This study investigates sociodemographic characteristics associated with RSV immunoprophylaxis. Methods: A cross-sectional survey was conducted from November 2023 through March 2024 among a convenience sample of parents of infants aged &lt;8 months who received newborn care or pediatric ambulatory care at a single academic institution in Central Pennsylvania, USA. Logistic regression examined sociodemographic factors associated with RSV immunoprophylaxis uptake. Given the nirsevimab shortage during the 2023–2024 RSV season, a sensitivity analysis was completed for intended immunoprophylaxis. Results: Among 118 participants, 66.9% received RSV immunoprophylaxis while 74.5% intended to receive nirsevimab. Higher income, private insurance, out-of-home childcare, and an adult/partner working in healthcare were associated with intended nirsevimab receipt. Participation in the Women, Infants and Children program was associated with lower rates of intended nirsevimab receipt. Out-of-home childcare was associated with both RSV immunoprophylaxis uptake and intended nirsevimab receipt. Conclusions: Sociodemographic factors significantly influence the intent to receive nirsevimab and RSV immunoprophylaxis uptake. Having an adult/partner in healthcare was the most significant predictor for intent, suggesting that greater health literacy drives immunization intention. Enrollment in out-of-home childcare was the sole predictor of RSV immunoprophylaxis uptake. These findings highlight the importance of policy initiatives that promote equitable access to RSV immunoprophylaxis, including strategies to address socioeconomic barriers, improve health literacy, and ensure consistent availability of preventive agents for all infants.">
  <meta property="og:locale" content="en-us">
  
  <meta property="article:published_time" content="2025-10-15T00:00:00&#43;00:00">
  
  <meta property="article:modified_time" content="2025-10-15T00:00:00&#43;00:00">
  

  

  

  <title>Sociodemographic Factors, Intent-Uptake Disparities, and Nirsevimab Availability in Infant RSV Immunoprophylaxis | Center for Medical Genomics</title>

</head>
<body id="top" data-spy="scroll" data-target="#toc" data-offset="71" >

<nav class="navbar navbar-default navbar-fixed-top" id="navbar-main">
  <div class="container">

    
    <div class="navbar-header">
      
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse"
              data-target=".navbar-collapse" aria-expanded="false">
        <span class="sr-only">Toggle navigation</span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      
      <a class="navbar-brand" href="/"><img src="/img/logo.png" alt="Center for Medical Genomics"></a>
    </div>

    
    <div class="collapse navbar-collapse">

      
      
      <ul class="nav navbar-nav navbar-right">
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#about">
            
            <span>About</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#labs">
            
            <span>Labs</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#events">
            
            <span>Events</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#publications">
            
            <span>Publications</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#contact">
            
            <span>Contact</span>
            
          </a>
        </li>

        
        
      

      
      </ul>

    </div>
  </div>
</nav>

<div class="pub" itemscope itemtype="http://schema.org/CreativeWork">

  


  <div class="article-container">
    <h1 itemprop="name">Sociodemographic Factors, Intent-Uptake Disparities, and Nirsevimab Availability in Infant RSV Immunoprophylaxis</h1>
    <span class="pub-authors" itemprop="author">
      
      BJ Lipsett, BN Fogel, KE Shedlock, IM Paul, EW Schaefer, RE Gardner, LD Kaye, SD Hicks
      
    </span>
    <span class="pull-right">
      
<div class="share-box" aria-hidden="true">
  <ul class="share">
    <li>
      <a class="twitter"
         href="https://twitter.com/intent/tweet?text=Sociodemographic%20Factors%2c%20Intent-Uptake%20Disparities%2c%20and%20Nirsevimab%20Availability%20in%20Infant%20RSV%20Immunoprophylaxis&amp;url=%2fpublication%2f2025-10-pediatr_rep%2f"
         target="_blank" rel="noopener">
        <i class="fa fa-twitter"></i>
      </a>
    </li>
    <li>
      <a class="facebook"
         href="https://www.facebook.com/sharer.php?u=%2fpublication%2f2025-10-pediatr_rep%2f"
         target="_blank" rel="noopener">
        <i class="fa fa-facebook"></i>
      </a>
    </li>
    <li>
      <a class="linkedin"
         href="https://www.linkedin.com/shareArticle?mini=true&amp;url=%2fpublication%2f2025-10-pediatr_rep%2f&amp;title=Sociodemographic%20Factors%2c%20Intent-Uptake%20Disparities%2c%20and%20Nirsevimab%20Availability%20in%20Infant%20RSV%20Immunoprophylaxis"
         target="_blank" rel="noopener">
        <i class="fa fa-linkedin"></i>
      </a>
    </li>
    <li>
      <a class="weibo"
         href="http://service.weibo.com/share/share.php?url=%2fpublication%2f2025-10-pediatr_rep%2f&amp;title=Sociodemographic%20Factors%2c%20Intent-Uptake%20Disparities%2c%20and%20Nirsevimab%20Availability%20in%20Infant%20RSV%20Immunoprophylaxis"
         target="_blank" rel="noopener">
        <i class="fa fa-weibo"></i>
      </a>
    </li>
    <li>
      <a class="email"
         href="mailto:?subject=Sociodemographic%20Factors%2c%20Intent-Uptake%20Disparities%2c%20and%20Nirsevimab%20Availability%20in%20Infant%20RSV%20Immunoprophylaxis&amp;body=%2fpublication%2f2025-10-pediatr_rep%2f">
        <i class="fa fa-envelope"></i>
      </a>
    </li>
  </ul>
</div>


    </span>

    

    
    <h3>Abstract</h3>
    <p class="pub-abstract" itemprop="text">Background/Objectives: Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and infant hospitalization in the US. RSV prevention evolved in 2023 as nirsevimab and maternal RSV pre-fusion vaccine became available for healthy newborns and infants. This study investigates sociodemographic characteristics associated with RSV immunoprophylaxis. Methods: A cross-sectional survey was conducted from November 2023 through March 2024 among a convenience sample of parents of infants aged &lt;8 months who received newborn care or pediatric ambulatory care at a single academic institution in Central Pennsylvania, USA. Logistic regression examined sociodemographic factors associated with RSV immunoprophylaxis uptake. Given the nirsevimab shortage during the 2023–2024 RSV season, a sensitivity analysis was completed for intended immunoprophylaxis. Results: Among 118 participants, 66.9% received RSV immunoprophylaxis while 74.5% intended to receive nirsevimab. Higher income, private insurance, out-of-home childcare, and an adult/partner working in healthcare were associated with intended nirsevimab receipt. Participation in the Women, Infants and Children program was associated with lower rates of intended nirsevimab receipt. Out-of-home childcare was associated with both RSV immunoprophylaxis uptake and intended nirsevimab receipt. Conclusions: Sociodemographic factors significantly influence the intent to receive nirsevimab and RSV immunoprophylaxis uptake. Having an adult/partner in healthcare was the most significant predictor for intent, suggesting that greater health literacy drives immunization intention. Enrollment in out-of-home childcare was the sole predictor of RSV immunoprophylaxis uptake. These findings highlight the importance of policy initiatives that promote equitable access to RSV immunoprophylaxis, including strategies to address socioeconomic barriers, improve health literacy, and ensure consistent availability of preventive agents for all infants.</p>
    

    
    <div class="row">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading">Type</div>
          <div class="col-xs-12 col-sm-9">
            
            <a href="/publication/#2">
              Journal article
            </a>
            
          </div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>
    

    
    <div class="row">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading">Publication</div>
          <div class="col-xs-12 col-sm-9"><em>Pediatric Reports</em></div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>
    

    <div class="row">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading">Date</div>
          <div class="col-xs-12 col-sm-9" itemprop="datePublished">
            October, 2025
          </div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>

    <div class="row" style="padding-top: 10px">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading" style="line-height:34px;">Links</div>
          <div class="col-xs-12 col-sm-9">

            

















<a class="btn btn-primary btn-outline" href="https://doi.org/10.3390/pediatric17050109" target="_blank" rel="noopener">
  DOI
</a>



          </div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>

    <div class="space-below"></div>

    <div class="article-style"></div>

    





  </div>
</div>



<footer class="site-footer">
  <div class="container">

    

    <p class="powered-by">

      &copy; 2025 Center for Medical Genomics &middot; 

      Powered by the
      <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
      <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

      <span class="pull-right" aria-hidden="true">
        <a href="#" id="back_to_top">
          <span class="button_icon">
            <i class="fa fa-chevron-up fa-2x"></i>
          </span>
        </a>
      </span>

    </p>
  </div>
</footer>


<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <button type="button" class="close btn-large" data-dismiss="modal">&times;</button>
        <h4 class="modal-title">Cite</h4>
      </div>
      <div>
        <pre><code class="modal-body tex"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-primary btn-outline js-copy-cite" href="#" target="_blank">
          <i class="fa fa-copy"></i> Copy
        </a>
        <a class="btn btn-primary btn-outline js-download-cite" href="#" target="_blank">
          <i class="fa fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

    

    
    

    

    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.2.1/jquery.min.js" integrity="sha512-3P8rXCuGJdNZOnUx/03c1jOTnMn3rP63nBip5gOP2qmUh5YAdVAvFZ1E+QLZZbC1rtMrQb+mah3AfYW11RUrWA==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.3/imagesloaded.pkgd.min.js" integrity="sha512-umsR78NN0D23AzgoZ11K7raBD+R6hqKojyBZs1w8WvYlsI+QuKRGBx3LFCwhatzBunCjDuJpDHwxD13sLMbpRA==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.3.7/js/bootstrap.min.js" integrity="sha512-iztkobsvnjKfAtTNdHkGVjAYTrrtlC7mGp/54c40wowO7LhURYl3gVzzcEqGl/qKXQltJ2HwMrdLcNUdo+N/RQ==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.4/isotope.pkgd.min.js" integrity="sha512-VDBOIlDbuC4VWxGJNmuFRQ0Li0SKkDpmGyuhAG5LTDLd/dJ/S0WMVxriR2Y+CyPL5gzjpN4f/6iqWVBJlht0tQ==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.2.5/jquery.fancybox.min.js" integrity="sha256-X5PoE3KU5l+JcX+w09p/wHl9AzK333C4hJ2I9S5mD4M=" crossorigin="anonymous"></script>
    
    
    <script src="/js/hugo-academic.js"></script>
    

    
    
      
      
      <script src="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/highlight.min.js" integrity="sha256-/BfiIkHlHoVihZdc6TFuj7MmJ0TWcWsMXkeDFwhi0zw=" crossorigin="anonymous"></script>
      

      

      

      <script>hljs.initHighlightingOnLoad();</script>
    

    
    

  </body>
</html>

